Barclays has confirmed a Neutral rating on the European pharmaceuticals, biotechnology and life sciences complex as it looks toward 2027, but analysts led by James Gordon signaled a move away from the previous positive tilt.
The note cites an anticipated decline in late-stage pipeline optionality in 2027, with peak pipeline readout potential estimated at about $50 billion versus roughly $75 billion in 2026. Alongside this, Barclays projects slightly slower large-cap top-line growth next year, forecasting 7% in local currency compared with 8% in 2026.
Analysts also highlighted the sector's approach toward substantial patent expiries - approximately $70 billion in 2031 and $50 billion in 2032 - as another factor informing the more cautious stance.
Valuation and macro view
Barclays reports that its large-cap forward price-to-earnings ratio for the sector remains at 15 times, which the analysts say is "not establishing a market premium." Given the quieter pipeline environment and a modest deceleration in growth for major companies, the bank prefers exposure to biotech, mid-cap and Specialty names where optionality and differentiated growth appear more appealing.
The analysts also expect life sciences companies to perform relatively better than broader pharma in 2027, forecasting roughly two percentage points of faster growth versus 2026.
Stock-level positioning
Within large-cap names, Barclays is Overweight AstraZeneca and Roche. AstraZeneca is cited for 2027 pipeline optionality and potential re-rating dynamics, while Roche is highlighted for long-duration growth and a breast cancer launch. Conversely, Barclays is Underweight GSK, noting that the new CEO's re-rating appears largely complete, the company faces a quieter 2027 and is moving closer to HIV loss of exclusivity.
In biotech, the bank is Overweight Genmab and Argenx, pointing to Genmab's oncology risk-reward profile and Argenx's combination of rapid growth and pipeline optionality. Barclays is Underweight Lakefront, referencing limited disclosure, a thin pipeline and a weak mergers-and-acquisitions track record.
Among mid-cap and Specialty names, Barclays is Overweight Bayer, Galderma and Grifols, while it turns Underweight on Ipsen due to risks from generic competition and margin pressure.
For life sciences companies, the bank is Overweight Lonza, Sartorius and Sartorius Stedim Biotech, but remains Underweight Diasorin because of execution risk and limited visibility.
Recent rating moves and market reaction
Barclays also announced a number of individual rating changes in the note: Hikma Pharmaceuticals was upgraded to Equal Weight from Underweight; Ipsen was downgraded to Underweight from Equal Weight; and Zealand Pharma was downgraded to Equal Weight from Overweight. The note recorded immediate market responses, with Hikma rising 1.4% in European trading by 10:31 GMT while Ipsen dropped more than 4%.
Alongside the positioning and rating changes, the research communication included forecast and price-target updates across Barclays' 28-stock coverage universe and issued positive Catalyst Alert reports on Genmab and Lundbeck ahead of the fourth quarter.
Implications
Barclays' revised stance signals a more cautious allocation approach within European pharma for 2027, favoring companies and sub-sectors that retain pipeline optionality, clearer growth trajectories or lifecycle exposure to durable end-markets. The bank's emphasis on biotech, mid-cap and Specialty names, and on specific life sciences firms, reflects a preference for differentiated growth and operational visibility amid an otherwise quieter late-stage development calendar.